Reliability of Minimally Trained Operator's Velocity-Time Integral Measurement Guided by Artificial Intelligence VTI
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jun 27, 2024
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how effectively a new technology, called UltraSight AI, can help less experienced medical staff measure an important heart function known as the Left Ventricular Outflow Tract (LVOT) Velocity-Time Integral (VTI). This measurement is crucial for understanding how well blood is flowing in critically ill patients, especially those showing signs of low blood flow, like low blood pressure or changes in consciousness. The goal is to see if these minimally trained operators can obtain reliable measurements when guided by the AI, compared to expert doctors' results.
To participate in this study, patients must be at least 18 years old and currently hospitalized in an Intensive Care Unit (ICU) where they need fluid treatment due to signs of low blood flow. Some examples of these signs include a significant drop in blood pressure, skin changes, or decreased urine output. Participants will undergo a measurement process while being monitored closely. It's important to note that patients with certain heart conditions or those in emergency situations may not be eligible for this trial. Overall, this study aims to improve the accuracy of heart function measurements, which could lead to better care for critically ill patients.
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • All patients aged 18 and more
- Hospitalized in ICU, in whom fluid administration is considered necessary by the clinician in charge, based on the presence of hypoperfusion criterion:
- • \>10% decrease in mean arterial pressure with respect to baseline value
- • Skin mottling, oliguria (\<0,5 ml/kg/h)
- • change in the level of consciousness
- • hyperlactatemia
- • decrease in central venous oxygen saturation Affiliation to a French social security system (beneficiary or legal) Participant's or next of kin non-opposition or emergency procedure
- Exclusion Criteria:
- • Patients with atrial fibrillation, due to the higher variability in LVOT VTI; Patient on Emergency Medical Assistance; Patient under guardianship, curatorship, deprived of liberty.
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Limoges, , France
Paris, , France
Paris, , France
Patients applied
Trial Officials
Bernard MD Cholley, PhD
Principal Investigator
Assistance Publique - Hôpitaux de Paris
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported